Pulmonx Corporation
LUNG · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $83,789 | $68,675 | $53,662 | $48,416 |
| % Growth | 22% | 28% | 10.8% | – |
| Cost of Goods Sold | $21,788 | $17,923 | $13,797 | $12,786 |
| Gross Profit | $62,001 | $50,752 | $39,865 | $35,630 |
| % Margin | 74% | 73.9% | 74.3% | 73.6% |
| R&D Expenses | $17,570 | $18,080 | $15,397 | $13,063 |
| G&A Expenses | $94,235 | $89,807 | $0 | $0 |
| SG&A Expenses | $102,135 | $94,607 | $83,105 | $69,871 |
| Sales & Mktg Exp. | $7,900 | $4,800 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $119,705 | $112,687 | $98,502 | $82,934 |
| Operating Income | -$57,704 | -$61,935 | -$58,637 | -$47,304 |
| % Margin | -68.9% | -90.2% | -109.3% | -97.7% |
| Other Income/Exp. Net | $1,810 | $1,663 | $67 | -$1,014 |
| Pre-Tax Income | -$55,894 | -$60,272 | -$58,570 | -$48,318 |
| Tax Expense | $500 | $571 | $353 | $343 |
| Net Income | -$56,394 | -$60,843 | -$58,923 | -$48,661 |
| % Margin | -67.3% | -88.6% | -109.8% | -100.5% |
| EPS | -1.44 | -1.6 | -1.59 | -1.35 |
| % Growth | 10% | -0.6% | -17.8% | – |
| EPS Diluted | -1.44 | -1.6 | -1.59 | -1.35 |
| Weighted Avg Shares Out | 39,111 | 37,975 | 37,097 | 36,129 |
| Weighted Avg Shares Out Dil | 39,111 | 37,975 | 37,097 | 36,129 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,061 | $5,568 | $1,529 | $400 |
| Interest Expense | $3,507 | $3,232 | $1,066 | $829 |
| Depreciation & Amortization | $1,593 | $1,948 | $1,513 | $867 |
| EBITDA | -$50,794 | -$55,092 | -$55,991 | -$46,622 |
| % Margin | -60.6% | -80.2% | -104.3% | -96.3% |